Everything You Need to Know About Hospital-acquired pneumonia for Step 1

Hospital-acquired pneumonia (HAP) is one of those Step questions where a single detail—timing—unlocks the whole vignette. The organism list, antibiotic choices, and “why is this patient suddenly hypoxic on day 4?” all hinge on understanding what hospital exposure does to airway flora, host defenses, and resistance patterns. Let’s build a clean, high-yield framework you can use on both Step 1 and Step 2.

---

Core definition (know this cold)

Hospital-acquired pneumonia (HAP)

• Pneumonia that develops $\ge$ 48 hours after hospital admission
• Not incubating at the time of admission

Ventilator-associated pneumonia (VAP)

• Subset of HAP: pneumonia that develops $\ge$ 48 hours after endotracheal intubation

High-yield distinction: HAP vs aspiration pneumonitis

• HAP/VAP: infection (often resistant organisms), fever + leukocytosis + new infiltrate.
• Aspiration pneumonitis: chemical injury from gastric contents (often rapid onset after aspiration), may be afebrile early; can progress to secondary bacterial aspiration pneumonia.

---

Why hospitals change the game: pathophysiology & microbiology

Pathophysiology (Step 1 mechanisms → Step 2 management)

Hospitalization increases pneumonia risk via:

• Colonization with hospital flora (oropharynx + upper airway)
  • Broad-spectrum antibiotics, prolonged stay, ICU, and devices select for resistant bacteria.
• Microaspiration around endotracheal tube cuff (VAP classic)
• Impaired clearance
  • Sedation, supine positioning, weak cough, underlying lung disease
• Biofilms on devices
  • Endotracheal tubes and suction circuits can harbor organisms.

Common pathogens (high yield)

Think “MRSA + Pseudomonas + other gram-neg rods.”

First Aid cross-reference (Pulmonary/Infectious):

• Pneumonias: typical vs atypical patterns, aspiration, and major bacterial causes (look under Respiratory infections + pneumonia tables).
• Pseudomonas and S. aureus are repeatedly emphasized as nosocomial pathogens.

---

Risk factors you should recognize in vignettes

Strong HAP/VAP risk factors

• Mechanical ventilation
• ICU admission
• Hospitalization $\ge$ 5 days
• Prior IV antibiotics within ~90 days (classic “drug-resistant risk” cue)
• Structural lung disease (bronchiectasis, severe COPD)
• Immunosuppression (steroids, transplant, neutropenia)
• Tube feeds, supine positioning (aspiration risk)
• Recent dialysis or frequent healthcare exposure (often grouped with resistant risk)

---

Clinical presentation (what shows up on Step)

Typical HAP/VAP presentation:

• New or worsening cough ± sputum (may be minimal in intubated)
• Fever, leukocytosis (or leukopenia in severe sepsis)
• Hypoxemia / increased oxygen requirement
• New infiltrate on chest imaging

VAP-specific bedside clues:

• Increased ventilator requirements
• Purulent tracheal secretions
• Worsening PaO₂/FiO₂ ratio (acute oxygenation decline)

High-yield pitfall: Atelectasis can cause fever/hypoxemia early post-op, but HAP definition is $\ge$ 48 hours after admission and should have new infiltrate + infectious signs.

---

Diagnosis: what Step expects you to do

Practical diagnostic criteria (USMLE-level)

You generally need:

• New lung infiltrate on CXR (or CT if unclear) PLUS
• Clinical evidence of infection: fever, leukocytosis, purulent secretions, worsening oxygenation

Workup (what to order before antibiotics—when feasible)

• Blood cultures (2 sets)
• Respiratory cultures
  • VAP: endotracheal aspirate; sometimes bronchoscopy/BAL depending on severity/institution
• Basic labs: CBC, CMP, lactate if septic
• Consider procalcitonin in real life; for Step, don’t over-weight it.

Imaging pearl:

• CXR may be portable and imperfect in ICU—if the story screams VAP but CXR is equivocal, the test often still wants you to treat empirically.

---

Treatment: empiric antibiotics (the algorithm Step loves)

Step 1 principle

HAP/VAP empiric therapy must cover MRSA + Pseudomonas (often double coverage if high resistance risk).

Step 2 execution: pick empiric therapy based on MRSA risk + Pseudomonas resistance risk

1) MRSA coverage (add if risk factors or high unit prevalence)

• Vancomycin or Linezolid

2) Antipseudomonal beta-lactam (choose one)

• Piperacillin-tazobactam
• Cefepime
• Ceftazidime
• Imipenem or Meropenem
• Aztreonam (if severe beta-lactam allergy)

3) Second antipseudomonal agent (add in high-risk situations)

Add ONE of:

• Levofloxacin or Ciprofloxacin (antipseudomonal fluoroquinolone)
  or
• Aminoglycoside (amikacin, gentamicin, tobramycin)

When do you add double Pseudomonas coverage? High-yield triggers:

• Prior IV antibiotics within ~90 days
• Septic shock / high mortality risk
• High local resistance rates
• Structural lung disease (esp. bronchiectasis)

De-escalation (testable stewardship concept)

• Start broad, then narrow once cultures/susceptibilities return.
• Typical total duration is often ~7 days if clinical response is good (Step 2 may test “shorter courses reduce resistance and complications”).

---

Quick “choose the regimen” table (memorize-friendly)

---

High-yield associations & board-style clues

Organism clues

• MRSA: post-influenza pneumonia, cavitary lesions possible, severe necrotizing pneumonia; in HAP/VAP assume risk with ICU/vent/previous antibiotics.
• Pseudomonas: ventilated/ICU, bronchiectasis, CF; can be aggressive with bacteremia.
• Klebsiella: classically alcoholism/diabetes/aspiration risk; thick “currant jelly” sputum (more classic for community, but can be nosocomial too).

Complications to recognize

• Sepsis/septic shock
• Lung abscess (esp. aspiration, anaerobes)
• Empyema/parapneumonic effusion
• ARDS (worsening oxygenation, diffuse bilateral opacities)

“This is not pneumonia” traps

• Pulmonary embolism: sudden dyspnea/pleuritic pain, tachycardia; may have normal CXR.
• Atelectasis: post-op low-grade fever, improves with incentive spirometry.
• Volume overload: crackles + cardiomegaly + pleural effusions; responds to diuresis.

---

First Aid cross-references (where this lives)

Use these to anchor your review (edition-dependent headings vary):

• Respiratory infections → Pneumonia: typical vs atypical, aspiration patterns
• Gram-positive/Gram-negative organism sections:
  • Staph aureus (MRSA)
  • Pseudomonas (nosocomial, oxidase +, blue-green pigment, fruity odor—extra ID hooks)
• Pharm: vancomycin/linezolid; antipseudomonal penicillins, cephalosporins (cefepime/ceftazidime), carbapenems, aztreonam, fluoroquinolones, aminoglycosides

---

Mini rapid-review (what to recall in 15 seconds)

• HAP = pneumonia $\ge$ 48 hours after admission; VAP = $\ge$ 48 hours after intubation
• Major culprits: MRSA + Pseudomonas + gram-negative rods
• Diagnose with new infiltrate + infectious signs (fever, leukocytosis, purulence, hypoxemia)
• Treat empirically with MRSA coverage (vanc/linezolid) + antipseudomonal beta-lactam ± second antipseudomonal if high resistance risk
• De-escalate to culture-directed therapy